Abstract
OBJECTIVE: To evaluate the efficacy of paclitaxel-coated balloon (PCB) in the treatment of extra-long femoropopliteal artery atherosclerotic disease (>30 cm). MATERIALS AND METHODS: Forty-nine patients with extra-long femoropopliteal artery atherosclerotic disease were treated with PCB alone in a single center from July 2016 to May 2018. Primary patency and freedom from clinically driven target lesion revascularization (FF-CDTLR) rates during 12 months were analyzed retrospectively. RESULTS: All patients were followed up for 18.2 ± 7.5 months, and the mean treated lesion length was 34.9 ± 3.7 cm. The primary patency rates were 87.8% (43/49) and 71.4% (35/49) at 6 and 12 months, respectively. FF-CDTLR was 91.8% (45/49) and 77.6% (38/49) at 6 and 12 months, respectively. No mortality or amputation occurred in these patients during the follow-up period. CONCLUSIONS: PCB has favorable clinical efficacy in patients with extra-long femoropopliteal artery atherosclerotic lesions.